Source: Eur Respir J 2013; 42: 636-646
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Alvar Agusti, Lisa D. Edwards, Bartolomé Celli, William MacNee, Peter M. A. Calverley, Hana Müllerova, David A. Lomas, Emiel Wouters, Per Bakke, Steve Rennard, Courtney Crim, Bruce E. Miller, Harvey O. Coxson, Julie C. Yates, Ruth Tal-Singer, Jørgen Vestbo. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013; 42: 636-646

Member's Comments

No comment yet.

Related content which might interest you: Survival in three years of COPD patients according to GOLD 2003 and GOLD 2014 Source: International Congress 2015 – Latest insights into the management of chronic respiratory diseases Year: 2015 Characteristics of GOLD 2011 grading system in the COPDGene cohort Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD Year: 2012 The 2006 and 2011 GOLD classifications and five-years mortality in COPD Source: Annual Congress 2013 –Monitoring symptoms and quality of life Year: 2013 Longitudinal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 A comparison of COPD patients with and without ACOS in the ECLIPSE study Source: Eur Respir J 2016; 47:1559-1562 Year: 2016 Mortality and exacerbation prediction by GOLD groups ABCD 2011 vs. 2017: analysis of the COPDGene cohort Source: International Congress 2017 – COPD management: new findings from large studies Year: 2017 Implementation of the GOLD 2017 disease classification in a real-life COPD cohort Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Distribution and significance of GOLD 2011 disease severity classification in patients with COPD in China: A national cross-sectional survey Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort Source: Eur Respir J, 57 (3) 2001339; 10.1183/13993003.01339-2020 Year: 2021 Heterogeneity in the clinical outcomes of COPD: lessons from the ECLIPSE study Source: International Congress 2017 – Heterogeneity in COPD inflammation: implications for therapy and clinical outcomes Year: 2017 2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the ’real-life’ DACCORD study Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 GOLD 2017 versus GOLD 2011 - comparison of the risk of exacerbations and mortality in COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 GOLD classification of COPD and subsequent mortality: findings from a cohort study Source: Annual Congress 2004 - Burden of obstructive lung diseases: costs, mortality and life impairment Year: 2004 Validation of the GOLD 2017 classification in a Chinese COPD cohort Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017 Phenotypes, treatable traits, GOLD groups and grades – how they predict mortality risk in COPD patients? (data from the Czech Multicenter Research Database of COPD) Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020 Comparing the 2007 and 2011 GOLD classifications as predictors of all-cause mortality and morbidity in COPD Source: International Congress 2014 – Monitoring COPD with different biomarkers Year: 2014 SGRQ-C distribution in the evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) cohort: Characteristics of COPD subjects with extreme score quintiles Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010 The impact of the three GOLD severity classifications of COPD (2001, 2011 and 2017) in the same population of patients. Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers Year: 2017 COPD comorbidities and risk assessment according to GOLD 2011 revision Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement Year: 2013 Metabolic and cardiovascular comorbidity in COPD patients classified using the GOLD 2011 assessment framework Source: Annual Congress 2012 - COPD epidemiology Year: 2012